[Pharmacokinetic and clinical studies on aztreonam in perinatal period].
Pharmacokinetic and clinical studies were carried out on aztreonam (AZT), a monobactam antibiotic with a high activity against Gram-negative bacteria. The results obtained are summarized as follows: 1. Following 2 g bolus intravenous injection, transfers of AZT to umbilical cord serum and amniotic fluid were found to be satisfactory. AZT level in amniotic fluid was higher than 1 micrograms/ml at 40 minutes after administration and it was at 3.7 micrograms/ml in 23.5 hours. 2. In the treatment of 9 patients with perinatal infections, clinical efficacies of AZT were judged excellent in 3 cases and good in 6 cases. 3. No side effects and abnormal laboratory findings due to the drug were observed in any case. These results indicate that AZT may be a useful antibiotic for the treatment of perinatal infections.
Sengoku
K
K
Department of Obstetrics and Gynecology, Asahikawa Medical College.
Shimizu
T
T
Haga
H
H
Inoue
R
R
Yamazaki
T
T
Mizoguchi
H
H
Torii
Y
Y
Sagawa
T
T
Saitou
S
S
D000328:Adult; D000653:Amniotic Fluid / Q000378:metabolism*; D001398:Aztreonam / Q000493:pharmacokinetics* / Q000627:therapeutic use; D001424:Bacterial Infections / Q000188:drug therapy*; D002821:Chorioamnionitis / Q000188:drug therapy; D005260:Female; D005312:Fetal Blood / Q000378:metabolism*; D005831:Genital Diseases, Female / Q000188:drug therapy*; D006801:Humans; D008431:Maternal-Fetal Exchange; D011247:Pregnancy; D011251:Pregnancy Complications, Infectious / Q000188:drug therapy*; D011704:Pyelonephritis / Q000188:drug therapy; D014591:Uterine Diseases / Q000188:drug therapy
D001398:Aztreonam